Astraveus is revolutionizing the field of CGT manufacturing with the Lakhesys™ platform, an end-to-end, cell foundry, that uses deep process optimization and single-use, microfluidic bioprocessors to deliver better results with reduced inputs.
By removing the need for large-scale infrastructure, reducing costs, and overcoming the logistical challenges typically associated with CGT manufacturing, Astraveus is seeking to transform patient access to these life-changing therapies.